Table 3.
Differences between subgroups of patients according to therapy modality or presence of CRSwNP
| Parameter | Therapy | CRSwNP | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Conventional | Omalizumab | P-value | No | Yes | P-value | |||||
| N = 38 | N = 10 | N = 33 | N = 15 | |||||||
| Median | IQR | Median | IQR | Median | IQR | Median | IQR | |||
| Periostin [ng/ml] | 28.03 | 13.1 | 20.3 | 8.9 | 0.025 | 25.13 | 11.9 | 32.17 | 9.1 | 0.087 |
| IgE [IU/ml] | 206.00 | 286.00 | 398.5 | 1004.00 | 0.491 | 217.00 | 589.3 | 181.00 | 286.00 | 0.982 |
| FeNO(50) [ppb] | 24.00 | 38.00 | 37.5 | 26.00 | 0.99 | 29.00 | 33.00 | 24.00 | 42.00 | 0.973 |
| eos % | 3.00 | 5.8 | 4.00 | 4.2 | 0.774 | 2.8 | 3.7 | 5.2 | 7.3 | 0.449 |
| AEC [eos/l] | 285.00 | 520.00 | 325.00 | 350.00 | 0.644 | 240.00 | 390.00 | 400.00 | 560.00 | 0.034 |
| ECP [μg/l] | 17.835 | 18.67 | 20.915 | 16.27 | 0.965 | 17.55 | 18.57 | 19.77 | 15.72 | 0.29 |
| FEV1 [l] | 2.19 | 1.04 | 2.32 | 0.46 | 0.397 | 2.265 | 0.985 | 2.015 | 0.94 | 0.17 |
| FEV1 (%nh) | 68.4 | 37.7 | 74.9 | 24.3 | 0.573 | 79.00 | 41.2 | 60.00 | 26.8 | 0.119 |
Mann-Whitney U test.